SUZHOU, China, July 28, 2025 /PRNewswire/ -- XellSmart Biopharmaceutical (Suzhou/Shanghai) Co., Ltd. achieved a significant milestone in its "world's first" China NMPA & US FDA-approved registrational clinical trial. This Phase I China registrational clinical trial for XS228 Cell Injection – the world's first "off-the-shelf", allogeneic, iPSC-derived, spinal neural progenitor cell therapy targeting major neurological...
NPST's innovative technology underscores its commitment to advancing digital payment adoption to meet diverse user needs, and its strategic adaptability establishes it as a...
LOS ANGELES, Jan. 15, 2025 /PRNewswire/ -- From Bangkok to New York, Tokyo to San Francisco, the Detective Chinatown Universe Continues to Amaze Audiences...
BANGKOK, Jan. 15, 2025 /PRNewswire/ -- The Thailand Board of Investment (BOI) announced today the approval by the Cabinet of updates and adjustments to...